Vireo Growth (VREOF) Gross Profit Growth (3y) (2023 - 2026)
Vireo Growth (VREOF) Gross Profit Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 7.62% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 4.71% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -7.64% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 12.55% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -9.13% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 24.80% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 0.95% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 83.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 83.99% |
| Dec 31, 2025 | 88.33% |
| Sep 30, 2025 | 57.67% |
| Jun 30, 2025 | 25.35% |
| Mar 31, 2025 | 70.80% |
| Dec 31, 2024 | 80.40% |
| Sep 30, 2024 | 34.06% |
| Jun 30, 2024 | 25.15% |
| Mar 31, 2024 | 29.67% |
| Dec 31, 2023 | 31.55% |
| Sep 30, 2023 | 38.53% |
| Jun 30, 2023 | 37.49% |
| Mar 31, 2023 | 42.68% |